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Abstract Cancer pain is generally treated with pharmaco-
logical measures, relying on using opioids alone or in
combination with adjuvant analgesics. Weak opioids are
used for mild-to-moderate pain as monotherapy or in a
combination with nonopioids. For patients with moderate-
to-severe pain, strong opioids are recommended as initial
therapy rather than beginning treatment with weak opioids.
Adjunctive therapy plays an important role in the treatment
of cancer pain not fully responsive to opioids administered
alone (ie, neuropathic, bone, and visceral colicky pain).
Supportive drugs should be used wisely to prevent and treat
opioids’ adverse effects. Understanding the pharmacokinetics,
pharmacodynamics,interactions,andcautions withcommonly
used opioids can help determine appropriate opioid selection
for individual cancer patients.
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Introduction
Cancer pain treatment is based on the analgesic ladder,
established in 1986 by the World Health Organization
(WHO; see Fig. 1)[ 1]. Cancer pain–management guidelines
in Europe are based on recommendations by the European
Association for Palliative Care (EAPC). Morphine use is
recommended by the Expert Working Group of the EAPC at
the third step of the WHO analgesic ladder, which comprises
additional opioids (ie, oxycodone, fentanyl, buprenorphine,
methadone, and hydromorphone) for the treatment of
moderate-to-severe pain intensity [2]. The use of an
analgesic ladder should be individualized with an appro-
priate application of supportive drugs (laxatives and
antiemetics) for the prevention and treatment of opioid
adverse effects [3] and nonpharmacological measures,
such as radiotherapy and invasive procedures (nerve
blockades and neurolytic blocks) [4].
Each step of the WHO analgesic ladder (ie, nonopioids,
weak opioids [analgesics for mild-to-moderate pain], and
strongopioids [opioidsfor moderate-to-severepainintensity])
may be accompanied with adjuvant analgesics (coanalgesics),
which can enhance opioid analgesia (Table 1). In patients
with bone pain, opioids may be combined with NSAIDs,
glucocorticoids, and bisphosphonates along with local or
systemic radiotherapy [5]. In patients with very severe
neuropathic pain, a combination of opioids and N-methyl
D-aspartate (NMDA)–receptor antagonists (eg, ketamine) is
recommended [6]. Opioid analgesics should be supple-
mented with spasmolytics in patients with visceral colicky
pain, especially in the course of bowel obstruction [7].
Opioids for Mild-to-Moderate Pain (Weak Opioids)
Tramadol
Tramadol displays opioid properties and acts on neuro-
transmission of noradrenalin and serotonin. Both enan-
tiomers act synergistically and improve analgesia without
W. Leppert (*)
Chair and Department of Palliative Medicine,
Poznan University of Medical Sciences,
Osiedle Rusa 25 A,
61–245 Poznan, Poland
e-mail: wojciechleppert@wp.pl
Curr Pain Headache Rep (2011) 15:271–279
DOI 10.1007/s11916-011-0201-7increasing adverse effects. Tramadol is metabolized in the
liver and excreted by the kidneys. The main metabolite is
O-desmethyltramadol (M1), which displays analgesic
activity with a higher affinity to μ-opioid receptors than
the parent compound; (+)-M1 has 300 to 400 times greater
affinity to μ-opioid receptors than tramadol and (−)-M1
mainly inhibits noradrenalin reuptake. Apart from O,N-
didesmethyltramadol (M5, which has weak analgesic
activity) and M1, other metabolites are inactive [8]. The
elimination half-life of tramadol is 5 to 6 h and that of M1
is 8 h. During oral administration, 90% of tramadol is
excreted by the kidneys and 10% in feces. Patients with
renal impairment show a decreased excretion of tramadol
and M1. In patients with advanced cirrhosis, there is a
decrease in tramadol metabolism with decrease of hepatic
clearance and increase in blood serum levels. In these
patients, elimination half-life is increased 2.5-fold. The
starting dose of immediate-release (IR) tramadol is 25 to
50 mg every 4 to 6 h and that of controlled-release (CR)
tablets or capsules is 50 to 100 mg twice daily; the daily
dose should not exceed 400 mg [9].
Patients devoid of cytochrome P450 2D6 (CYP2D6)
activity (poor metabolizers) need a tramadol dose higher by
30% than those with normal CYP2D6 activity (extensive
metabolizers) [10]. Tramadol analgesia depends on
CYP2D6 genotype, with less analgesia in poor metabolizers
being associated with lack of (+)-M1 formation [11].
Genotyping is helpful in patients with duplication of
CYP2D6 gene (ultrarapid metabolizers [UM]) who are at
greater risk to develop tramadol adverse effects [12￿].
Tramadol metabolism through CYP2D6 may cause inter-
actions with drugs inhibiting this enzyme (eg, cimetidine
and ranitidine).
Serotonin syndrome has been reported in patients taking
selective serotonin reuptake inhibitors (SSRIs) in conjunction
with tramadol or opioids (see Table 2)[ 13]. SSRIs (eg,
fluoxetine, paroxetine, and, to less extent, sertraline) used in
conjunction with tramadol may cause serotonin syndrome
because SSRIs inhibit tramadol metabolism and increase
serotonin level; generally, they should not be coadministered
with tramadol. Serotonin syndrome may appear with
Fig. 1 World Health
Organization three-step
analgesic ladder
Table 1 Common adjuvant analgesics used in different pain types
Bone pain
NSAIDs, paracetamol
Glucocorticoids (dexamethasone)
Bisphosphonates (pamidronate, zoledronate)
Local radiotherapy
Radioisotopes (strontium, samarium)
Neuropathic pain
Antidepressants (amitryptyline, nortriptyline, venlafaxine)
Anticonvulsants (gabapentin, pregabalin, carbamazepine)
Local anesthetics (lignocaine, bupivacaine)
NMDA-receptor antagonists (ketamine)
Visceral colicky pain:
Spasmolytics (hyoscine butylbromide, hyoscine hydrobromide,
glycopyrrolate)
NMDA N-methyl-d-aspartate; NSAIDS Nonsteroidal anti-inflammatory
drugs
Agitation
Restlessness
Headache
Diarrhea
Confusion
Increased heart rate and blood
pressure
Muscle twitching
Shivering
Fever
Seizure
Loss of consciousness
Table 2 Symptoms of serotonin
syndrome
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done, and venlafaxine. However, mianserin and mirtazapine do
not influence serotonin levels and do not inhibit CYP2D6, but
they are substrates of this enzyme [14].
The inhibition of tramadol metabolism may attenuate
analgesia due to (+)-M1 opioid analgesic activity. For
example, coadministration of ondansetron (a selective 5-
hydroxytryptamine receptor antagonist) blocks spinal
5-HT3 receptors and competitively inhibits CYP2D6.
Tramadol analgesia also may be impaired by coadministra-
tion of carbamazepine, which accelerates tramadol and M1
metabolism. Concomitant administration of tricyclic anti-
depressants increases the risk of seizures. Tramadol should
be avoided in patients with history of epilepsy. In rats and
mice, concomitant administration of tramadol and β-
blocker and the 5-HT1A/1B antagonist pindolol enhances
analgesia [15].
Respiratory depression is rare in the chronic use of
tramadol. When it does occur, respiratory depression is
connected with the opioid mode of tramadol action, so
naloxone should be administered. For example, respiratory
depression was reported in a cancer patient with renal
impairment (creatinine clearance 30 mL/min) and with UM
genotype after renal carcinoma resection [12￿]. As respira-
tory symptoms appeared more than 10 h after the first
tramadol dose, the accumulation of M1 was the cause. The
patient recovered after intravenous (IV) naloxone bolus
administration (0.4 mg). This case highlights that tramadol
should not be prescribed in patients with UM genotype and
renal impairment [12￿].
Dihydrocodeine
Dihydrocodeine (DHC) is a semisynthetic analogue of
codeine. Apart from analgesic and antitussive activity, DHC
also is used in the treatment of opioid addiction. After
subcutaneous (SC) administration of DHC, 30 mg, analge-
sia is similar to that induced by 10 mg of morphine. After
parenteral administration, DHC is twice as potent as
codeine. Bioavailability of DHC after oral administration
is 20%, which indicates that its analgesia after oral
administration is slightly stronger than that of codeine
(bioavailability after oral administration equals 30%–40%).
After oral administration of DHC, the maximal serum
concentration appears after 1.7 h, plasma half-life varies
from 3.5 to 5.5 h, and analgesia lasts 4 h. Ammon et al.
[16] assessed DHC pharmacokinetics in 12 extensive
metabolizers of CYP2D6. They received a single oral
DHC dose of 60 mg, then after 60 h, they were treated for
3 days with 60 mg dosed twice daily; for the next 3 days
with 90 mg twice daily; and for 3 subsequent days with
120 mg twice daily. In the 60 to 120 mg DHC dose range,
pharmacokinetics of DHC and dihydromorphine (DHM)
displayed linear characteristics; area under the curve
(AUC), maximum serum concentration (Cmax), and mini-
mum serum concentration at steady state (Cssmin) for both
compounds increased depending on the drug dose [17, 18].
Even though DHM displays higher affinity (about 100-fold)
to the μ-opioid receptors and exhibits higher analgesic
activity in comparison to the parent compound, the role of
DHM and its glucuronides in DHC analgesia has not been
unequivocally established. The starting dose of IR DHC is
usually 30 mg every 4 to 6 h, and that of CR tablets is
60 mg twice daily [17].
Renal clearance and the clearance to DHC metabolites,
glucuronidation, and O-demethylation to DHC-6-glucuronide
(DHC-6-G) and DHM, respectively, are not dose dependent,
which indicates thatmetabolismandexcretionofDHC andits
metabolites are not dose dependent. Moreover, the ratio of
DHC to DHM for AUC does not change depending on the
dose, which suggests a lack of saturation effect of the O-
demethylation process of DHC to DHM depending on
CYP2D6 in patients normally metabolizing the substrates of
this enzyme. Pharmacokinetic parameters were similar after
single and multiple doses of 60 mg of DHC [16]. Single-dose
and multiple-dose pharmacokinetics of IR and CR DHC
formulations provide support for a twice-daily dosage
schedule of CR DHC. DHC is metabolized in the liver to
its main metabolites: DHM, DHC-6-G, and nordihydroco-
deine (NORDHC). NORDHC is further glucuronidated to
NORDHC-6-glucuronide and O-demethylated to nordihy-
dromorphine (NDHM). DHM undergoes glucuronidation to
DHM-3-glucuronide (DHM-3-G) and DHM-6-glucuronide
(DHM-6-G) and N-demethylation to NDHM. It may be
concluded that DHC undergoes the first pass effect after oral
administration, which is connected with the formation of
significantly higher amount of metabolites after oral than
after parenteral administration [18]. Studies performed to
date [19, 20] indicate that DHC analgesia is independent of
CYP2D6 activity [21].
Codeine
Codeine is a methylated morphine derivative that is found
naturally, along with morphine, in the poppy seed. Codeine
displays analgesic and antitussive activity. Codeine is
available as IR and CR formulations but also in the form
of paracetamol-combined preparations. IR codeine is
administered every 4 to 6 h in chronic pain with a starting
single dose of about 30 mg. The daily doses of DHC and
codeine usually do not exceed 240 mg and 300 mg,
respectively; when these analgesics are ineffective, opioids
for moderate-to-severe pain (strong opioids) are introduced.
Codeine is metabolized in the liver and its bioavailability
is 30% to 40% after oral administration. After oral
administration of codeine, maximal plasma concentration
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3.5 h and analgesia maintained for 4 to 6 h (IR
formulations). Codeine is partially metabolized to morphine
and its metabolites and to codeine metabolites norcodeine
(NORC) and codeine-6-glucuronide (C-6-G) [22]. The
analgesic effect of codeine is about equal to 1/10th of
morphine analgesia. Polymorphism of CYP2D6 is respon-
sible for the formation of morphine, and its metabolites
may affect codeine analgesia. Other codeine metabolites,
C-6-G predominantly, also display analgesic activity and
contribute to codeine analgesia [23]. In healthy volunteers,
codeine is metabolized to C-6-G (81.0%±9.3%), NORC
(2.16%±1.44%), morphine (0.50%±0.39%), morphine-
3-glucuronide (M-3-G; 2.10%±1.24%), morphine-6-
glucuronide (M-6-G; 0.80%±0.63%), and normorphine
(NORM; 2.44%±2.42%). The half-life of codeine is
1.47 h±0.32 h, and that of C-6-G is 2.75 h±0.79 h. The
plasma AUC of C-6-G is about tenfold higher than that of
codeine. Protein binding of codeine and C-6-G in vivo is
56.1%±2.5% and 34.0%±3.6%, respectively [24].
Lötsch et al. [22] explored the contributions from
codeine and its metabolites to central nervous analgesic
effects independent from O-demethylation of codeine to
morphine. A pharmacokinetic/pharmacodynamic fit of
the miotic effects by use of morphine as the only active
compound was most significantly (P<0.0001) improved
when C-6-G as a second active moiety was added.
CYP2D6-dependent formation of morphine does not
explain exclusively the central nervous effects of co-
deine, and C-6-G is the most likely additional active
moiety with possible contribution of NORC and the
parent compound [22].
Gasche et al. [25] depicted a patient who received oral
codeine in a daily dose of 75 mg (25 mg three times a day)
and who, after 4 days of treatment, experienced respiratory
depression. The patient recovered after IVadministration of
naloxone (0.4 mg). The cause of the symptoms was
CYP2D6 UM phenotype. The patient was concomitantly
treated with clarithromycin and voriconazole, both
known inhibitors of CYP3A4. This together with
CYP2D6 gene duplication led to the reduced clearance of
codeine. Blood concentrations of M-3-G and M-6-G were
substantially elevated, also due to renal failure [25].
Recent reports [26, 27] indicate that there is a significant
risk of respiratory depression in infants whose mothers
with CYP2D6 UM and UGT2B7￿2/￿2 genotypes taking
codeine during breastfeeding [28￿]. Guidelines for mater-
nal codeine use during breastfeeding were issued in
Canada [29], but it seems safer to not use codeine and
substitute it with other analgesics in this patient group.
Apart from morphine glucuronides, codeine and its
metabolites (C-6-G and NORC) also contribute to analgesic
effects [22, 23].
Opioids for Moderate-to-Severe Pain (Strong Opioids)
Morphine
Morphine still is the standard drug for the treatment of
severe cancer pain and is a comparator for other strong
opioids [30￿￿]. This is predominantly due to large clinical
experience and different routes of morphine administration
(eg, oral, SC, IV, intrathecal, and topical). Morphine is a
hydrophilic opioid and a pure opioid agonist that acts
predominantly through the activation of μ-opioid receptors.
Plasma half-life of IR formulations equals 2 to 3 h and the
bioavailability after oral morphine administration equals
about 30% to 40%. Morphine undergoes glucuronidation;
thus, there is little risk of pharmacokinetic interactions with
other drugs.
The active metabolite responsible for analgesia is
morphine-6-glucuronide (M-6-G). The accumulation of
morphine and M-6-G may cause nausea and vomiting,
sedation, and finally, respiratory depression. Morphine-3-
glucuronide (M-3-G) is devoid of analgesic properties but
may be responsible for neurotoxic effects and opioid-
induced hyperalgesia (paradoxical pain) [31]. The main
drawback of morphine is the fact that M-3-G and M-6-G
may accumulate especially in patients with renal impair-
ment and renal failure, leading to possible intense adverse
effects associated with accumulation of metabolites. In
severe pain syndromes, a change from oral to parenteral or
intrathecal route of morphine administration may be
beneficial. In case of renal problems, a switch from
morphine to other opioids, such as fentanyl, methadone,
or buprenorphine, is recommended. Similar to other
opioids, morphine often causes constipation; therefore, the
use of laxative prophylaxis is recommended.
Numerous oral CR formulations of morphine, designed
for 12-hour and 24-hour administration, were developed
[32]. Local administration of morphine prevents systemic
adverse effects. The starting daily dose of oral morphine is
usually 20 to 30 mg (for opioid-naïve patients) or 40 to
60 mg (for patients unsuccessfully treated with weak
opioids) [33￿]. The dose of parenteral (SC or IV) morphine
is one third of the morphine oral dose [34].
Fentanyl
Fentanyl is a lipophilic opioid, a μ-opioid receptor agonist,
with analgesic effect about 100 times more potent than that
of morphine. In chronic pain treatment, transdermal
fentanyl (TF) patches are applied, usually on the upper
trunk. There are five types of patches that release 12, 25,
50, 75, and 100 μg/h equal to 2.1-, 4.2-, 8.4-, 12.6-, and
16.8-mg fentanyl dose per day, respectively. Patches are
changed every 72 h. Patients need access to short-acting
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fentanyl tablets, oral transmucosal fentanyl citrate [OTFC],
or fentanyl spray) during TF therapy to effectively manage
breakthrough-pain episodes. Fentanyl is metabolized main-
ly to inactive norfentanyl; thus, it may be used in patients
with renal impairment. Because the fentanyl metabolic
pathway is through CYP3A4, the drugs inhibiting or
inducing this enzyme should be avoided. Caution is
recommended when using drugs metabolized via CYP3A4.
In comparison to morphine, the advantages of TF include
milder constipation, nausea, and drowsiness [35].
When starting TF in opioid-naïve or strong opioid–naïve
patients, one patch at a dose of 12 μg/h or 25 μg/h,
respectively, is recommended. TF also may be used in
opioid switch, especially in patients treated with morphine
who suffer from intractable constipation. In an open-label
study of 16 patients with cancer pain unable to take oral
opioids, TF was effective and well tolerated [36]. A good
analgesic effect was achieved in 11 patients, with a partial
effect in an additional 2 patients. TF was effective and well
tolerated in patients formerly treated with weak opioids that
did not provide satisfactory analgesia [37]. The indications
for TF include patients’ preferences, intense constipation
during morphine treatment, morphine intolerance, nausea,
and vomiting. TF should not be used in patients with
unstable pain syndromes, especially with neuropathic pain
component due to the long plasma half-life (20 h) of the
drug, which hinders quick and effective dose titration.
Fentanyl may be successfully used by other routes (eg, SC,
IV, inhaled, buccal) in the treatment of breakthrough pain
[38].
Oxycodone
Oxycodone is a semisynthetic thebaine derivative, a strong
opioid that displays a significant affinity to κ-opioid
receptors along with agonistic effect mediated by μ-opioid
receptors. Limited cross-tolerance is observed between
oxycodone and morphine in rats and in clinical studies
[39]. In comparison to morphine, oxycodone possesses
lower affinity to μ-opioid receptors and similar lipid
solubility. Oxycodone permeates the blood–brain barrier
very quickly, which may explain its stronger analgesic
effect in comparison to other opioids. Oxycodone does not
display immunosuppressive effects in experimental studies.
It has high oral bioavailability (60%–87%); the plasma half-
life is 2 to 3 h after IV administration, 3 h after treatment
with IR oral solution, and 8 h after CR tablets. The
bioavailability of rectal administration is similar to oral
route (61%), but it displays greater variability.
Oxycodone is metabolized in the liver primarily to
noroxycodone through CYP3A4 and, to a much less extent,
to oxymorphone via CYP2D6. Noroxycodone is metabo-
lized to noroxymorphone through CYP2D6, and oxy-
morphone is metabolized to noroxymorphone by
CYP3A4. However, analgesia observed after oxycodone
administration relies primarily on the parent compound.
Noroxycodone has 17% of the potency of oxycodone.
Oxymorphone, in spite of high affinity for μ-opioid
receptors, is produced in very small amounts. Noroxymor-
phone is produced in a significant amount and displays
significant affinity for opioid receptors. However, the
blood–brain barrier is extremely impermeable to noroxy-
morphone; thus, its role in analgesia is negligible. Low
blood–brain barrier permeability is also characteristic of
noroxycodone and oxymorphone [40].
In patients with liver cirrhosis and hepatic diseases, the
oxycodone dose should be reduced by half. Oxycodone is
excreted through the kidneys. In patients with renal
insufficiency, the oxycodone dose also should be reduced.
In patients with renal failure, the oxycodone half-life is
prolonged and ranges from 1.8 to 26 h. The elimination of
noroxycodone and oxymorphone also is impaired in
patients with renal failure. CYP2D6 polymorphism proba-
bly does not influence oxycodone analgesia and adverse
effects. Sertraline minimally inhibits CYP2D6 and intensi-
fies adverse effects of oxycodone (eg, hallucinations,
tremors), whereas fluoxetine and quinidine (significant
CYP2D6 inhibitors) do not intensify oxycodone adverse
effects. Oxycodone reduces oral bioavailability of cyclo-
sporine by half. In healthy patients, rifampin, a CYP3A4
inducer, greatly decreased oral and IV oxycodone AUC by
86% and 53%, respectively (P<0.001), and modestly
reduced analgesia and increased plasma metabolite-to–
parent compound ratios for noroxycodone and noroxymor-
phone (P<0.001) [41]. A pharmacodynamic interaction of
oxycodone with other drugs acting on the central nervous
system, such as benzodiazepines, neuroleptics, and anti-
depressants, may intensify oxycodone adverse effects,
especially sedation, and respiratory depression may be
intensified in the case of patients who are more sensitive to
opioids.
Buprenorphine
Buprenorphine is a partial μ-opioid–receptor agonist and κ-
receptor antagonist. A ceiling analgesic effect may be
obtained at high doses (ie, 15 mg); however, such high
doses are not used in clinical practice. The analgesic
potency of buprenorphine is about 100 times greater than
oral morphine [42]. Buprenorphine may be administered
sublingually due to low oral bioavailability at doses of 0.2
t o0 . 8m g ,u s u a l l y3t i m e sd a i l y .I ta l s om a yb e
administered by parenteral route (SC or IV).
Buprenorphine is metabolized to the active metabolite
norbuprenorphine via CYP3A4. The parent compound and
Curr Pain Headache Rep (2011) 15:271–279 275norbuprenorphine undergo glucuronidation; thus, the risk of
pharmacokinetic interactions with other drugs is low.
Compared with morphine, buprenorphine less frequently
induces constipation, nausea, and vomiting, which is
probably associated with higher lipophilicity. Buprenor-
phine is mainly excreted with feces (2/3 of the drug is
excreted with feces); therefore, it may be used in patients
with renal failure. Respiratory depression is rare; however,
when the symptom appears, naloxone injection should be
administered at a dose of 2 mg, followed by continuous
infusion (4 mg/h). Buprenorphine displays antihyperalgesic
activity and may be used successfully in the treatment of
neuropathic pain [43].
Buprenorphineisadministeredintransdermalpatches(TB)
releasing 35, 52.5, and 70 μg/h, which correspond to 0.8, 1.2,
and 1.6 mg/d, respectively. The patches are changed every 84
to 96 h. In some countries, patches releasing 5 and 10 μg/h,
changed weekly, are available. The starting dose for strong
opioid–naïve patients is usually one patch of 35 μg/h.
However,opioid-naivepatientsandthosewithrenalorhepatic
impairment may start with a dose of 17.5 μg/h. The treatment
isusuallywell-tolerated.Atdosesupto140μg/h,TBdoesnot
display ceiling analgesia [44￿]. Breakthrough pain may be
treated with sublingual buprenorphine tablets or with IR
morphine administered by oral or parenteral route.
Hydromorphone
Hydromorphone has about 5 to 10 times more potent
analgesic effect than morphine and similar pharmacody-
namic properties. Hydromorphone analgesia is due to μ-
opioid–receptor agonist effects. After hydromorphone
administration, analgesia lasts for about 4 to 6 h and the
plasma half-life is about 2.5 h. The drug is metabolized
mainly to hydromorphone-3-glucuronide that may accumu-
late in patients with renal failure and induce neurotoxic
adverse effects. Hydromorphone in small amount also is
metabolized to 6-hydroxy-hydromorphone, but its role is
unknown. Due to glucuronidation, the risk of hydro-
morphone pharmacokinetic interactions with other drugs
seems to be low [45]. Adverse effects are similar to those of
morphine; however, hydromorphone less frequently indu-
ces nausea and vomiting, constipation, itching, and proba-
bly more slowly develops tolerance to analgesia [46].
Hydromorphone is especially useful for patients requiring
high opioid doses via parenteral route due to strong
analgesic effects and the possibility of administering small
volumes of the drug in SC injections.
Methadone
Methadone is a synthetic opioid and a racemate of dextroro-
tatory (S-methadone) and levorotatory (D-methadone) isomers.
Methadoneactivatesμ-,κ-, and Δ-receptors (D-methadone); it
displays moderate antagonistic effect to NMDA receptors (both
enantiomers)andstronglyinhibitsthereuptakeofserotoninand
noradrenalin in the central nervous system (S-methadone). In
high doses, methadone blocks potassium channels required for
rapid cardiac muscle repolarization, which may explain the risk
of developing ventricular arrhythmia.
Methadone is administered mostly to patients with
cancer pain who undergo opioid switch; usually, methadone
is given every 8 h. In comparison to morphine, 10 times
less demand for laxatives and 2 times less nausea and
vomiting were observed. Methadone may be administered
as the first strong opioid to patients who have been treated
with opioids for moderate pain or to opioid-naïve patients
(the starting dose is usually 3–5 mg every 8 h) [47].
Methadone can be administered to patients with renal
impairment. It has weak immunosuppressive effect and
does not suppress the functioning of natural killer cells.
Methadone is tenfold less expensive than the CR morphine
and 25-fold cheaper than TF.
Methadone is a highly lipophilic and basic drug with a
high distribution volume (4.1 L/kg±0.65 L/kg) and a high
affinity to tissues, where it accumulates after multiple
administrations (in brain, lung, liver, gut, kidney, and
muscles). The high affinity to tissues, together with a
gradual and retarded release to plasma, is the cause of a
prolonged half-life. The bioavailability of the drug after
oral administration oscillates between 70% and 90%. The
half-life is about 24 h, but it occurs in the range of 8 to
120 h. Analgesia lasts for 6 to 12 h. A stable level is
reached within 2 to 4 days. Methadone is metabolized
mostly via liver enzymes, but also in the intestine wall via
N-demethylation to inactive metabolites. The main enzyme
responsible for methadone N-demethylation is CYP3A4
with a lesser CYP1A2 and CYP2D6 involvement and a
significant CYP2B6 role. The drug is excreted mainly via
the alimentary tract, but also through kidneys (depending
on the urine pH). In chronic renal disease, methadone does
not accumulate; in severe renal failure, a dose reduction
may be considered. Methadone is not eliminated in the
process of hemodialysis. Methadone is more difficult to use
than other opioids due to complicated pharmacokinetics,
numerous drug interactions, and possible QT prolongation;
therefore, it should be used by physicians experienced in
management of chronic pain [48].
Tapentadol
Tapentadol chloride ([−]-[1R,2R]-3-[3-Dimethylamino-1-
ethyl-2-methyl-propyl]-phenol hydrochloride) is an opioid
with two analgesic mechanisms: 1) agonist of μ-opioid
receptors with 50 times less affinity than morphine, and 2)
inhibition of norepinephrine reuptake [49]. Bioavailability
276 Curr Pain Headache Rep (2011) 15:271–279after oral administration is over 30%, the drug is metabo-
lized to inactive metabolites through glucuronidation and
excreted via kidneys [50]. In experimental studies tapenta-
dol is effective in the treatment of neuropathic pain and in
inflammatory pain. In clinical studies conducted in patients
with low back pain, those with postoperative pain, and
those with osteoarthritis, IR tapentadol at doses of 50, 75,
and 100 mg had more favorable adverse-effects profiles
with less intense gastrointestinal adverse effects (ie, nausea,
vomiting, constipation) in comparison to IR oxycodone at
doses of 10 and 15 mg. Clinical studies on tapentadol use in
patients with cancer pain have not been published.
Conclusions
Opioids are usually effective when administered alone or
with adjuvant analgesics. The traditional WHO step-by-step
Table 4 Comparison among strong opioids for moderate-to-severe severity pain
Opioid
a Main mode of action Attributes Precaution Typical starting dose
Morphine μ-Opioid receptor agonist May be administered by
different routes: oral, SC, IV,
IT, local
Active metabolites may
accumulate and cause adverse
effects in renal failure
5–10 mg q 4 h (IR);
20–30 mg q 12 h (CR)
Fentanyl μ-Opioid receptor agonist Less constipation than
morphine; safe in patients
with renal impairment
Fever may increase absorption;
should not be used for quick
dose titration (unstable pain)
One patch 25 μg/h q 72 h;
12.5 μg/h q 72 h for older
patients with liver or
hepatic impairment
Oxycodone μ-a n dκ-Opioid receptor
agonist
Less CNS adverse effects than
morphine
May accumulate in renal failure 5 mg q 4–6 h (IR);
10–20 mg 12 h (CR)
Buprenorphine Partial μ-Opioid receptor
agonist, weak κ-opioid
receptor antagonist
Less constipation than
morphine; safe in patients
with renal impairment
Fever may increase absorption;
should not be used for quick
dose titration (unstable pain)
One patch 35 μg/h q 84 h;
17.5 μg/h q 84–96 h for
older patients with liver or
hepatic impairment
Hydromorphone μ-Opioid receptor agonist Useful for patients requiring
high opioid doses; less
pruritus, nausea/vomiting,
and sedation than morphine
Parent compound and
metabolites may accumulate
in renal failure
1–2 mg q 4 h (IR);
2–4 mg q 12 h (CR)
Methadone μ - and δ-Opioid receptor
agonist, NMDA-receptor
antagonist, NOR- and
5HT-reuptake blocker
Useful for patients with severe
neuropathic pain and renal
failure
Possible QT interval
prolongation; numerous drug
interactions; long plasma
half-life
3–5m gq8h
Tapentadol μ-Opioid receptor agonist
and NOR-reuptake blocker
Less adverse effects from GI
tract than oxycodone
May accumulate in renal failure 50 mg q 4–6 h (IR);
100 mg q 12 h (CR)
aTaken orally
5HT Serotonin; CNS central nervous system; CR controlled-release formulation; GI gastrointestinal; IR Immediate-release formulation; IT
Intrathecal; IV Intravenous; NMDA N-methyl-D-aspartate receptors; NOR Noradrenaline; SC Subcutaneous
Table 3 Comparison among weak opioids for mild-to-moderate severity pain
Opioid
a Main mode of action Attributes Precaution Typical starting dose
Tramadol μ-Opioid receptor agonist,
5HT- and NOR-reuptake
blocker
Less constipation than other
opioids
Nausea should be prevented by
antiemetics; analgesia impaired
in CYP2D6 poor metabolizers
25–50 mg q 4–6 h (IR);
50–100 mg q 12 h (CR)
Dihydrocodeine μ-Opioid receptor agonist Useful for patients with
moderate pain, cough, and
dyspnea
Constipation should be prevented
by laxatives
30 mg q 4–6 h (IR); 60 mg q
12 h (CR)
Codeine μ-Opioid receptor agonist Useful for patients with
moderate pain, cough, and
dyspnea; combined
formulations with
paracetamol
Constipation should be prevented
by laxatives; should not be
administered in CYP2D6
ultrarapid metabolizers
30 mg q 4–6 h (IR); 60 mg q
12 h (CR)
aTaken orally
5HT Serotonin; CR Controlled-release formulations; CYP2D6 Cytochrome P450 2D6; IR Immediate-release formulations; NOR Noradrenaline; q
Every
Curr Pain Headache Rep (2011) 15:271–279 277approach should be used individually, based on the clinical
assessment of pain type and intensity. Patients with severe
pain intensity should use strong opioids (opioids for
moderate-to-severe pain) without climbing up the analgesic
ladder. Opioids may be combined with nonopioid analge-
sics and adjuvant analgesics appropriate for a given pain
type. Understanding important attributes of commonly used
opioids can help assist selection (Tables 3 and 4).
In case of lack of efficacy of orally or transdermally
administered opioids, it may be beneficial to change the route
of administration to parenteral or intrathecal. Another possi-
bility is opioid switch that may improve analgesia and reduce
adverse effects. A good example may be patients suffering
from severe constipation who may benefit when switching
from morphine to TF and from codeine or DHC to tramadol.
A newer approach is the concomitant use of two opioids,
although little evidence supports such procedure. Future
studies may address genetic disposition responsible for
individual patients’ response to opioid analgesics [51￿￿].
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